% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{GimnezDejoz:281887,
author = {Giménez-Dejoz, Joan and Kolář, Michal H. and Ruiz,
Francesc X. and Crespo, Isidro and Cousido-Siah, Alexandra
and Podjarny, Alberto and Barski, Oleg A. and Fanfrlík,
Jindřich and Parés, Xavier and Farrés, Jaume and Porté,
Sergio},
title = {{S}ubstrate {S}pecificity, {I}nhibitor {S}electivity and
{S}tructure-{F}unction {R}elationships of {A}ldo-{K}eto
{R}eductase 1{B}15: {A} {N}ovel {H}uman {R}etinaldehyde
{R}eductase},
journal = {PLoS one},
volume = {10},
number = {7},
issn = {1932-6203},
address = {Lawrence, Kan.},
publisher = {PLoS},
reportid = {FZJ-2016-01549},
pages = {e0134506 -},
year = {2015},
abstract = {Human aldo-keto reductase 1B15 (AKR1B15) is a newly
discovered enzyme which shares $92\%$ amino acid sequence
identity with AKR1B10. While AKR1B10 is a well characterized
enzyme with high retinaldehyde reductase activity, involved
in the development of several cancer types, the enzymatic
activity and physiological role of AKR1B15 are still poorly
known. Here, the purified recombinant enzyme has been
subjected to substrate specificity characterization, kinetic
analysis and inhibitor screening, combined with structural
modeling. AKR1B15 is active towards a variety of carbonyl
substrates, including retinoids, with lower kcat and Km
values than AKR1B10. In contrast to AKR1B10, which strongly
prefers all-trans-retinaldehyde, AKR1B15 exhibits superior
catalytic efficiency with 9-cis-retinaldehyde, the best
substrate found for this enzyme. With ketone and dicarbonyl
substrates, AKR1B15 also shows higher catalytic activity
than AKR1B10. Several typical AKR inhibitors do not
significantly affect AKR1B15 activity. Amino acid
substitutions clustered in loops A and C result in a
smaller, more hydrophobic and more rigid active site in
AKR1B15 compared with the AKR1B10 pocket, consistent with
distinct substrate specificity and narrower inhibitor
selectivity for AKR1B15.},
cin = {INM-9 / IAS-5},
ddc = {500},
cid = {I:(DE-Juel1)INM-9-20140121 / I:(DE-Juel1)IAS-5-20120330},
pnm = {574 - Theory, modelling and simulation (POF3-574)},
pid = {G:(DE-HGF)POF3-574},
typ = {PUB:(DE-HGF)16},
UT = {WOS:000358836800146},
pubmed = {pmid:26222439},
doi = {10.1371/journal.pone.0134506},
url = {https://juser.fz-juelich.de/record/281887},
}